Table 4.
Parameters | Univariate Analysis | Multivariable Analysis | ||
---|---|---|---|---|
HR (95% CI) | P Value | aHR (95% CI) | P Value | |
Age, y | 1.05 (1.04–1.07) | <.0001 | 1.02 (1.00–1.04) | .040 |
Male | 1.63 (.94–2.85) | .084 | … | |
Hemoglobin | 0.88 (.74–1.03) | .12 | … | |
White blood cell | 1.14 (1.02–1.27) | .023 | … | |
Platelet | 0.99 (.99–1.00) | .0065 | 0.995 (.991–1.000) | .031 |
Alanine aminotransferase | 1.01 (1.00–1.02) | .0030 | … | |
Albumin | 0.87 (.83–.90) | <.0001 | … | |
Total bilirubin | 1.02 (.98–1.07) | .31 | … | |
International normalized ratio | 2.14 (.46–9.97) | .33 | … | |
Creatinine | 1.02 (1.01–1.03) | .00020 | … | |
C-reactive protein | 1.14 (1.11–1.17) | <.0001 | 1.07 (1.02–1.12) | .0065 |
Lactate dehydrogenase (per 100 U/L) | 2.17 (1.34–3.52) | .0031 | 1.48 (1.15–1.91) | .0027 |
Neutrophil-to-lymphocyte ratio | 1.24 (1.18–1.30) | <.0001 | … | |
Circulatory system disease | 5.62 (3.31–9.54) | <.0001 | … | |
Digestive system disease | 3.48 (1.58–7.70) | .0020 | … | |
Diabetes mellitus | 10.06 (5.90–17.15) | <.0001 | 3.21 (1.72–6.00) | .00026 |
Malignant tumor | 2.88 (.70–11.83) | .14 | … | |
Nervous system disease | 1.41 (.20–10.19) | .73 | … | |
Respiratory disease | 5.90 (1.84–18.89) | .0028 | … | |
Chronic kidney disease | 5.47 (1.33–22.46) | .018 | … | |
Bacterial or viral coinfection | 1.41 (.44–4.52) | .56 | … | |
Hypoxia during follow-up | 2.22 (.95–5.17) | .066 | … | |
Lopinavir-ritonavir during follow-up | 0.95 (.56–1.62) | .85 | … | |
Ribavirin during follow-up | 1.11 (.65–1.88) | .71 | … | |
Interferon beta during follow-up | 1.14 (.66–1.99) | .64 | … | |
Steroid during follow-up | 4.02 (1.90–8.51) | .0003 | … |
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; COVID-19, coronavirus disease 2019; HR, hazard ratio.